Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.
Steinbuch SC, Lüß AM, Eltrop S, Götte M, Kiesel L.
Int J Mol Sci. 2024 Apr 13;25(8):4306. doi: 10.3390/ijms25084306.
Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, Zhang T, Wang H, Yu Z, Mai J, Shen H, Nixon B, Li M, Brentjens RJ, Ma X.
Nat Commun. 2020 Dec 8;11(1):6298. doi: 10.1038/s41467-020-20140-0.
A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, Oikkonen J, Bulanova D, Pietras EJ, Voßgröne K, Chen YJ, Erkan EP, Dai J, Lundgren A, Grønning Høg MK, Larsen IM, Lamminen T, Kaipio K, Huvila J, Virtanen A, Engelholm L, Christiansen P, Santoni-Rugiu E, Huhtinen K, Carpén O, Hynninen J, Hautaniemi S, Vähärautio A, Wennerberg K.
Dev Cell. 2023 Jun 19;58(12):1106-1121.e7. doi: 10.1016/j.devcel.2023.04.012. Epub 2023 May 5.
M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY, Xie H, Yuan J, Jiang XY, Yong JH, Zeng D, Dou YY, Xiao SS.
Cancer Biol Ther. 2019;20(7):956-966. doi: 10.1080/15384047.2018.1564567. Epub 2019 May 7.
Ovarian Mucinous Tumor Presenting Atypical Lobular Endocervical Glandular Hyperplasia-Like Appearance in a Patient With Germline STK11 p.F354L Variant: A Case Report.
Yoshida H, Hiranuma K, Nakahara M, Kobayashi-Kato M, Tanase Y, Uno M, Shiraishi K, Ishikawa M, Kato T.
Int J Surg Pathol. 2024 Apr;32(2):394-400. doi: 10.1177/10668969231177256. Epub 2023 May 24.
Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis.
Dundr P, Gregová M, Němejcová K, Bártů M, Hájková N, Hojný J, Stružinská I, Fischerová D.
Diagn Pathol. 2020 Jul 21;15(1):91. doi: 10.1186/s13000-020-01012-z.
Ovarian Mucinous Carcinoma with a Yolk sac Tumor-Like Component: A Report of Three Cases with a Literature Review for Prognostic Analysis.
Tsujimura M, Fujimoto M, Minamiguchi S, Miyamoto T, Ueda A, Hamanishi J, Mandai M, Haga H.
Int J Surg Pathol. 2023 Aug;31(5):765-771. doi: 10.1177/10668969221133346. Epub 2022 Oct 30.
Tumor cells promote immunosuppression in ovarian cancer via a positive feedback loop with MDSCs through the SAA1-IL-1beta axis.
Hu H, Yang M, Huang B, Ding J, Zhu Y, Xu X, Yin B, Zhou H, Huang T, Li M, Kou Y, Rahim Z, Li A, Wang W, Han L.
J Exp Clin Cancer Res. 2025 Sep 30;44(1):277. doi: 10.1186/s13046-025-03536-y.
Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer.
Dogra S, Elayapillai SP, Qu D, Pitts K, Filatenkov A, Houchen CW, Berry WL, Moxley K, Hannafon BN.
Cancer Lett. 2023 Dec 1;578:216437. doi: 10.1016/j.canlet.2023.216437. Epub 2023 Oct 12.
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC Jr, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA.
JCI Insight. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929.
